Patchara in the phase four we still need the GPP guidlines, like Jessica has said it is quite challenging on how to engage the stakeholders at this level. However what we must know that at this level the number of key stakeholders has increased. Governments at this level should be involved because implications related to policy issues are mostly likely required at this level.
Discussions regarding the provision of the approved medical product are at this level, debates regarding the cost effectiveness and uptake are hers. Advocacy at this level is increased to increase buy-in of important stakeholders.
